Omeprazol Mabo (Omeprazole)

Omeprazole, the active ingredient in Omeprazol Mabo, is a proton pump inhibitor presented as a tablet for oral use. It irreversibly blocks the H+/K+ ATPase enzyme in gastric parietal cells, thereby markedly reducing gastric acid secretion. This action provides relief from symptoms and promotes healing in acid‑related gastrointestinal disorders such as gastro‑esophageal reflux disease, erosive esophagitis, and peptic ulcer disease in adult patients.

GNH USA supplies Omeprazol Mabo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeprazole acts on the gastric proton pump to decrease acid production, making it useful for several acid‑related conditions. - Gastro‑esophageal reflux disease (GERD): reduces reflux symptoms and promotes esophageal healing. - Erosive esophagitis: heals erosive lesions in the esophagus. - Peptic ulcer disease: facilitates ulcer healing and prevents recurrence. - Helicobacter pylori eradication (as part of combination therapy): enhances the effectiveness of antibiotic regimens. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion.

Omeprazole may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: loose stools often transient. - Nausea: occasional feeling of queasiness. - Abdominal pain: mild discomfort in the stomach area. - Flatulence: increased intestinal gas.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis risk. - Acute interstitial nephritis: kidney inflammation. - Severe allergic reactions: rash, swelling, anaphylaxis. - Osteoporotic fractures: increased risk with long‑term use. - Hypomagnesemia: low magnesium levels with prolonged therapy.

When using Omeprazol Mabo, certain precautions should be observed to ensure safety and effectiveness. - Assess renal function: dose adjustment may be needed in severe renal impairment. - Evaluate hepatic status: use with caution in patients with liver disease. - Limit duration: avoid long‑term use unless medically justified to reduce fracture risk. - Monitor for infections: be aware of increased risk of gastrointestinal infections. - Review concomitant medications: consider potential interactions affecting drug levels. - Store at room temperature: keep below 25°C, in the original packaging, protected from moisture.

Omeprazole can affect the pharmacokinetics of several medicines, requiring attention to possible interactions.

Major Interactions (Avoid): - Antiretroviral protease inhibitors (e.g., atazanavir): reduced absorption, may compromise efficacy. - Antifungal agents (e.g., ketoconazole, itraconazole): decreased bioavailability. - Clopidogrel: reduced activation leading to diminished antiplatelet effect. - Warfarin: increased anticoagulant effect, heightened bleeding risk. - Methotrexate (high dose): decreased renal clearance, risk of toxicity.

Moderate Interactions (Monitor Closely): - Digoxin: increased serum levels, monitor for toxicity. - Phenytoin: altered metabolism, may require dose adjustment. - Diazepam: increased plasma concentration, watch for sedation. - Iron supplements: reduced absorption, separate dosing by at least 2 hours. - Vitamin B12: long‑term use may impair absorption, monitor levels.